Virion Therapeutics Revenue
Biotechnology Research • 
Newark, Delaware, United States • 1-10 Employees
Virion Therapeutics revenue & valuation
| Annual revenue | $684,440 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,200,000 |
| Total funding | $95,000 |
Key Contacts at Virion Therapeutics
Janice Bennett
Director Cmc
Paula Z. Macdonald
Chief Technology Officer
Company overview
| Headquarters | 7 Creek Bend Court, Newark, DE 19711, US |
| Phone number | +18008419303 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Cancer, Immunotherapy, Infectious Diseases |
| Founded | 2018 |
| Employees | 1-10 |
| Socials |
Virion Therapeutics Email Formats
Virion Therapeutics uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@viriontx.com), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@viriontx.com | 66.7% |
{first name}{last name} | johndoe@viriontx.com | 33.3% |
About Virion Therapeutics
At Virion Therapeutics, We Believe a Future Free of Cancer and Chronic Infectious Diseases Is Within Reach Driven by science, our mission is to revolutionize the immunotherapy treatment landscape, focusing on the development of novel, adaptable, and accessible CD8+T cell-based technologies. Our transformative platform is first in its class, offering a unique methodology that combines innovative and established approaches to elicit a superior CD8+T cell response. Novel genetically encoded checkpoint modifiers are delivered alongside optimized target-specific antigens via an immunogenic and adaptable viral vector platform that promotes potent, prolonged, and broad CD8+T cell responses. With potential applications across a range of cancers and chronic infectious diseases, our proprietary technology provides us with a robust pipeline. Our lead product, VRON-0200, is under investigation as a potential functional cure for the treatment of chronic hepatitis B virus (HBV) – a first-in-human clinical study is planned to initiate in late 2022. Founded in 2018 to advance technology licensed from The Wistar Institute, we have assembled a world-class management team and an industry-leading global Board of Directors, with proven experience in the biotechnology sector, as well as extensive preclinical and clinical expertise in antiviral, vaccine, oncology, and immuno-oncology.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Virion Therapeutics has 3 employees across 3 departments.
Departments
Number of employees
Virion Therapeutics Tech Stack
Discover the technologies and tools that power Virion Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Video players
JavaScript libraries
JavaScript libraries
JavaScript libraries
Programming languages
Security
Blogs
Analytics
UI frameworks
WordPress plugins
Tag managers
Hosting
Switzerland
Frequently asked questions
4.8
40,000 users
